- BMS-589154)
-
- $1.00 / 1g
-
2021-01-06
- CAS:1686149-74-5
- Min. Order: 1g
- Purity: 85.0-99.8%
- Supply Ability: 20ton
|
| 4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-6-[4-(5-methyl-2-oxo-1-piperidinyl)phenyl]-7-oxo-1H-pyrazolo[3,4-c]pyridine-3-carboxamide Basic information |
Product Name: | 4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-6-[4-(5-methyl-2-oxo-1-piperidinyl)phenyl]-7-oxo-1H-pyrazolo[3,4-c]pyridine-3-carboxamide | Synonyms: | BMS-728626;1-(4-methoxyphenyl)-3-(morpholine-4-carbonyl)-6-(4-(2-oxopiperidin-1-yl)phenyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;Apixaban Amino acid impurity;Apixaban IMP;Apixaban Impurity I;4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-6-[4-(5-methyl-2-oxo-1-piperidinyl)phenyl]-7-oxo-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;Apixaban impurity 6/Apixaban Amino Acid Impurity/4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-6-[4-(5-methyl-2-oxo-1-piperidinyl)phenyl]-7-oxo-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopyrrolidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide | CAS: | 1686149-74-5 | MF: | C26H27N5O4 | MW: | 473.52 | EINECS: | | Product Categories: | | Mol File: | 1686149-74-5.mol | |
| 4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-6-[4-(5-methyl-2-oxo-1-piperidinyl)phenyl]-7-oxo-1H-pyrazolo[3,4-c]pyridine-3-carboxamide Chemical Properties |
Boiling point | 766.0±60.0 °C(Predicted) | density | 1.39±0.1 g/cm3(Predicted) | solubility | DMSO (Slightly), Methanol (Slightly) | pka | 15.01±0.20(Predicted) | form | Solid | color | White to Off-White | Stability: | Hygroscopic |
| 4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-6-[4-(5-methyl-2-oxo-1-piperidinyl)phenyl]-7-oxo-1H-pyrazolo[3,4-c]pyridine-3-carboxamide Usage And Synthesis |
Uses | An analytical standard impurity of Apixaban (A726700(P)), which is a potent, direct, selective, and orally active inhibitor of coagulation factor Xa. It is a potential new oral coagulant that may be useful prevention of venous thromboembolism in total hip, knee replacement orthopedic surgery and stroke in treatment of patient with venous thromboembolic disorder or with atrial fibrillation. |
| 4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-6-[4-(5-methyl-2-oxo-1-piperidinyl)phenyl]-7-oxo-1H-pyrazolo[3,4-c]pyridine-3-carboxamide Preparation Products And Raw materials |
|